Systemic Treatment for Hepatobiliary Cancers in First and Later Lines: Applying the Latest Data

Interact with an expert during a 1-hour, CME/CNE/CPE-certified live meeting examining recent advances and current best practices in treatment for hepatocellular carcinoma and biliary tract cancers. Register today!

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

  • Introduction and Overview
  • First-line Systemic Therapy for Advanced HCC: Current and Emerging Options
  • Second-line Therapy for Advanced HCC
  • Systemic Therapy Combinations for Early or Intermediate-Stage HCC: Current Evidence and Ongoing Trials
  • BTC: Current and Emerging Immunotherapy and Targeted Therapy Regimens
  • Audience Q&A

Events

Date / Time
Event Details

Faculty

Program Director
James M. Cleary, MD, PhD

Assistant Professor of Medicine
Harvard Medical School
Associate Director of Clinical Research
Gastrointestinal Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Program Director
Mark Yarchoan, MD

Assistant Professor
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins
Baltimore, Maryland

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate current and emerging systemic therapies into the treatment of patients with hepatocellular carcinoma and biliary tract cancers.

Target Audience
This educational program is intended for hepatologists, medical oncologists, radiation oncologists, surgical oncologists, nurses, pharmacists, and other healthcare professionals who treat patients with hepatocellular carcinoma and biliary tract cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate clinical data on the use of systemic treatment approaches for patients with early or intermediate-stage HCC
  • Plan optimal, individualized therapy approaches using immune checkpoint inhibitor-based regimens for patients with advanced or metastatic HCC, as clinically appropriate
  • Test tumors for biomarkers that can identify patients with hepatobiliary cancers suitable for targeted therapy
  • Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitors and targeted therapies in patients with HCC or BTC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-196-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.